Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
75 stopped studies mapped to Malignant Thyroid Gland Neoplasm and descendants · 92% state a reason
Over the 75 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | Phase 2 | terminated | Jan 15, 2016 | Eisai Inc. | Overall response rate was 3% (only 1 out of 33 participants had confirmed PR). | Other (stated, no rule matched) |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | Phase 2 | withdrawn | Nov 13, 2014 | University of Texas Southwestern Medical Center | study was on hold for protocol redesign; decided to not move forward with study. | Other (stated, no rule matched) |
| NCT02472080 | Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II…(THYGEMOX) | Phase 2 | terminated | Jun 15, 2015 | Assistance Publique - Hôpitaux de Paris | inefficiency | Other (stated, no rule matched) |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome… | Phase 1 / Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual,primary endpoint reached \& investigator left NIH. | Investigator |
| NCT00926978 | Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients… | N/A | terminated | Jun 24, 2009 | Medstar Health Research Institute | Institutional RDRC dissolved | Other (stated, no rule matched) |
| NCT02947399 | Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone… | N/A | terminated | Oct 27, 2016 | Medstar Health Research Institute | Institutional RDRC dissolved | Other (stated, no rule matched) |
| NCT00804830 | Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer | Phase 2 | terminated | Dec 9, 2008 | Region Skane | lack of response | Other (stated, no rule matched) |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and… | Phase 1 | withdrawn | Jul 13, 2016 | Vanderbilt-Ingram Cancer Center | Loss of funding support | Funding |
| NCT02778412 | ctDNA in Patients With Thyroid Nodules | — | terminated | May 19, 2016 | Pathway Genomics | Preliminary results indicated that this test had a number of false-negative results. | Other (stated, no rule matched) |
| NCT02726282 | Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross… | — | withdrawn | Apr 1, 2016 | Mayo Clinic | funding not available | Funding |
| NCT01865838 | A Study Into the Effect of Seprafilm in Open Total Thyroidectomy | N/A | terminated | May 31, 2013 | National Cancer Centre, Singapore | safety issue | Safety / toxicity |
| NCT01403324 | Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or…(DOSIMETA) | N/A | terminated | Jul 27, 2011 | Gustave Roussy, Cancer Campus, Grand Paris | Recruitment difficulties | Enrollment / accrual |
| NCT01994200 | Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa)…(ITCA-ThyCa) | Phase 1 / Phase 2 | withdrawn | Nov 25, 2013 | Jewish General Hospital | not stated | Not stated |
| NCT02516774 | A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With…(TAM-RT) | Phase 1 | withdrawn | Aug 6, 2015 | Gustave Roussy, Cancer Campus, Grand Paris | No patients enrolled | Enrollment / accrual |
| NCT01153945 | Association Between Cancer Cells and Normal Versus (Vs.) Low Levels of Thyroid Hormones… | — | withdrawn | Jun 30, 2010 | Meir Medical Center | The sponsor stopped the study. | Other (stated, no rule matched) |
| NCT00354523 | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma | Phase 1 / Phase 2 | terminated | Jul 20, 2006 | M.D. Anderson Cancer Center | Study closed following Phase I portion, insufficient activity to continue to Phase II. | Other (stated, no rule matched) |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid…(FACT) | Phase 2 / Phase 3 | terminated | Jul 26, 2007 | Mateon Therapeutics | Low rate of subject accrual | Enrollment / accrual |
| NCT01701349 | Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid…(FACT2) | Phase 3 | withdrawn | Oct 5, 2012 | Mateon Therapeutics | Expected inability to recruit study participants in a reasonable amount of time. | Enrollment / accrual |
| NCT00115739 | Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | Phase 2 | terminated | Jun 24, 2005 | University of Michigan Rogel Cancer Center | Study was closed early due to slow accrual | Enrollment / accrual |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00954837 | Assessment of Repeat Fine Needle Aspiration (FNA) to Detect Thyroid Cancer(CYT2THYR) | N/A | withdrawn | Aug 7, 2009 | Assistance Publique - Hôpitaux de Paris | administrative delays too long | Other (stated, no rule matched) |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | Phase 2 | withdrawn | Nov 29, 2012 | Eanm Research Ltd | Study was withdrawn due to unanticipated hassle in patient recruitment. | Enrollment / accrual |
| NCT00647140 | Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer(DOPMET) | Phase 2 | terminated | Mar 31, 2008 | Assistance Publique - Hôpitaux de Paris | Insuffisent recruitment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 15, 2019source: clinicaltrials